ABS Bio Buys Cureline, Enhancing Biospecimen Access and Execution
The add-on acquisition of Cureline by ABS Bio, a 3 Boomerang portfolio company, expands ABS Bio’s capabilities, geographic reach and client base while strengthening its end-to-end biospecimen services.
Therapeutic Programmes | 08/01/2026 | By News Bureau
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Evotec has reported advancement in its preclinical neuroscience collaboration with Bristol Myers Squibb, securing a payment of USD 25 Million to support the continued development of jointly pursued therapeutic programmes.
Therapeutic Programmes | 28/10/2025 | By Dineshwori | 170
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy